PE58199A1 - Quinoxalinadionas - Google Patents
QuinoxalinadionasInfo
- Publication number
- PE58199A1 PE58199A1 PE1998000128A PE00012898A PE58199A1 PE 58199 A1 PE58199 A1 PE 58199A1 PE 1998000128 A PE1998000128 A PE 1998000128A PE 00012898 A PE00012898 A PE 00012898A PE 58199 A1 PE58199 A1 PE 58199A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- compound
- solvate
- iii
- refers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) o SU SAL SODICA o SOLVATO, QUE TIENE UNA PUREZA DE AL MENOS 90% P/P. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE LA HIDROLISIS ACIDA o BASICA DE UN COMPUESTO DE FORMULA (II), R ES UN GRUPO DE FORMULA (III) o (IV) Y R1 Y R2 SON ALQUILO C1-C4 DE PREFERENCIA METILO o ETILO, ENTRE OTROS; QUE PUEDEN ESCINDIRSE POR HIDROLISIS; ESTANDO SEGUIDO POR: i)LA SEPARACION DEL ATROPOISOMERO DE FORMULA (I) CUANDO SE USA UN COMPUESTO DE FORMULA (II), R ES UN GRUPO DE FORMULA (III); ii)OPCIONALMENTE LA CONVERSION A SU SAL O SOLVATO. EL COMPUESTO (I) ES UN ANTAGONISTA SELECTIVO DEL RECEPTOR NMDA (N-METIL-D-ASPARTATO), SIENDO UTIL PARA EL TRATAMIENTO DE TRASTORNO NEURODEGENERATIVO AGUDO o UN TRASTORNO NEUROLOGICO CRONICO
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
| PCT/EP1997/000995 WO1997032873A1 (en) | 1996-03-09 | 1997-02-27 | Quinoxalinediones |
| GBGB9715783.8A GB9715783D0 (en) | 1997-02-27 | 1997-07-25 | Quinoxalinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE58199A1 true PE58199A1 (es) | 1999-06-11 |
Family
ID=10790134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000162A PE43398A1 (es) | 1996-03-09 | 1997-03-06 | Quinoxalinadionas |
| PE1998000128A PE58199A1 (es) | 1996-03-09 | 1998-02-23 | Quinoxalinadionas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000162A PE43398A1 (es) | 1996-03-09 | 1997-03-06 | Quinoxalinadionas |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6376490B1 (es) |
| EP (1) | EP0885212B1 (es) |
| JP (1) | JP3110467B2 (es) |
| KR (1) | KR100288099B1 (es) |
| CN (1) | CN1103770C (es) |
| AP (1) | AP767A (es) |
| AR (1) | AR006119A1 (es) |
| AT (1) | ATE208773T1 (es) |
| AU (1) | AU717972B2 (es) |
| BG (1) | BG63340B1 (es) |
| BR (1) | BR9707851A (es) |
| CA (1) | CA2248366C (es) |
| CO (1) | CO4770976A1 (es) |
| CZ (1) | CZ292792B6 (es) |
| DE (1) | DE69708269T2 (es) |
| DK (1) | DK0885212T3 (es) |
| DZ (1) | DZ2188A1 (es) |
| EA (1) | EA001730B1 (es) |
| ES (1) | ES2163742T3 (es) |
| GB (1) | GB9605027D0 (es) |
| HN (1) | HN1998000034A (es) |
| HR (1) | HRP970132A2 (es) |
| HU (1) | HUP9900975A3 (es) |
| ID (1) | ID18112A (es) |
| IL (1) | IL125491A (es) |
| IS (1) | IS4811A (es) |
| MA (1) | MA26422A1 (es) |
| NO (1) | NO984058L (es) |
| NZ (1) | NZ331060A (es) |
| OA (1) | OA10850A (es) |
| PE (2) | PE43398A1 (es) |
| PL (1) | PL329032A1 (es) |
| PT (1) | PT885212E (es) |
| SI (1) | SI0885212T1 (es) |
| SK (1) | SK283467B6 (es) |
| TN (1) | TNSN97044A1 (es) |
| TR (1) | TR199801782T2 (es) |
| TW (1) | TW454004B (es) |
| UY (1) | UY24482A1 (es) |
| WO (1) | WO1997032873A1 (es) |
| YU (2) | YU39698A (es) |
| ZA (1) | ZA971987B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
| WO1998038186A1 (en) * | 1997-02-27 | 1998-09-03 | Pfizer Limited | Quinoxalinediones |
| US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| DE10005150A1 (de) | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| CZ20023763A3 (cs) * | 2000-05-19 | 2003-03-12 | Merck Patent Gmbh | Derivát triazolu |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| MY145368A (en) * | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
| WO2005076295A1 (ja) | 2004-02-06 | 2005-08-18 | Yamaguchi University | エネルギー貯蔵デバイス用電極及びその製造方法 |
| JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| EP2150248A4 (en) * | 2007-01-16 | 2011-06-29 | Univ Johns Hopkins | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| CN101679383B (zh) * | 2007-05-17 | 2014-10-29 | 株式会社半导体能源研究所 | ***衍生物，和使用***衍生物的发光元件、发光器件和电子器件 |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| ES2481823T3 (es) | 2010-03-10 | 2014-07-31 | Probiodrug Ag | Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5) |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| CN104955809B (zh) * | 2013-02-07 | 2018-12-11 | 普雷斯特威克化学公司 | 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1，3，4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69132340T2 (de) * | 1990-11-06 | 2001-02-08 | Yamanouchi Pharma Co Ltd | Kondensiertes pyrazinderivat |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| WO1998038186A1 (en) * | 1997-02-27 | 1998-09-03 | Pfizer Limited | Quinoxalinediones |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE58199A1 (es) | Quinoxalinadionas | |
| EA200200628A1 (ru) | Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a | |
| BR9916576A (pt) | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 | |
| BR0308261A (pt) | Métodos extrativos para puruficação de sucralose | |
| DE69830504D1 (de) | Antithrombotische mitteln | |
| CY1109088T1 (el) | Μεθοδος για την παρασκευη υποκατεστημενων ενωσεων 3-αρυλο-βουτυλ-αμινης | |
| PA8546301A1 (es) | Resolucion de sal quiral | |
| AR030045A1 (es) | Composicion farmaceutica que contiene compuestos antibioticos de azalida , metodos para obtencion | |
| DE69912279D1 (de) | 5-ht1f agonisten | |
| BG66085B1 (bg) | Фенилаланинови производни | |
| EA200300172A1 (ru) | Метод обезболивания | |
| BR9901279A (pt) | Triciclicos substituìdos | |
| BRPI0410705A (pt) | forma cristalina de agonista de receptor 2 adrenérgico | |
| BR0314488A (pt) | Composto, composição farmacêutica e métodos de tratamento | |
| EA200200194A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
| BR9913457A (pt) | Neuroproteção | |
| EA022994B1 (ru) | Способ подавления толерантности к опиоидному анальгетику | |
| PA8532001A1 (es) | Bifenilcarboxamidas utiles como agentes reductores de lipidos | |
| PT1087986E (pt) | Undecanoato de 7alfa-metil-19-nortestosterona com actividade androgenica | |
| PA8542601A1 (es) | Bifenilcarboxamidas reductoras de lipidos | |
| ES2190422T3 (es) | Antagonistas selectivos de receptores de adenosina a2b. | |
| ES2162916T3 (es) | Derivados de acido pirimidin- o triazincarboxilico para el empleo como medicamentos. | |
| BR9804753A (pt) | Compostos de ácido picolìnico 5-substituìdo e processos para a sua produção. | |
| DE60036924D1 (de) | 5-ht1f agonisten | |
| BR9901275A (pt) | Triciclicos substituidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |